Lipitoids, which self-assemble with DNA and RNA, can serve as cellular delivery systems for antiviral therapies that could prevent COVID-19 and other coronavirus infections. (Illustration courtesy of R.N. Zuckermann)
Cellular delivery system developed at Berkeley Lab’s Molecular Foundry could be missing link in battle against SARS-CoV-2
A team of scientists from Stanford University is working with researchers at the Molecular Foundry, a nanoscience user facility located at the Department of Energy’s Lawrence Berkeley National Laboratory (Berkeley Lab), to develop a gene-targeting, antiviral agent against COVID-19.
Last year, Stanley Qi, an assistant professor in the departments of bioengineering, and chemical and systems biology at Stanford University and his team had begun working on a technique called PAC-MAN – or Prophylactic Antiviral CRISPR in human cells – that uses the gene-editing tool CRISPR to fight influenza.
But that all changed in January, when news of the COVID-19 pandemic emerged. Qi and his team were suddenly confronted with a mysterious new virus for which no one had a clear solution. “So we thought, ‘Why don’t we try using our PAC-MAN technology to fight it?’” said Qi.
Since late March, Qi and his team have been collaborating with a group led by Michael Connolly, a principal scientific engineering associate in the Biological Nanostructures Facility at Berkeley Lab’s Molecular Foundry, to develop a system that delivers PAC-MAN into the cells of a patient.
Like all CRISPR systems, PAC-MAN is composed of an enzyme – in this case, the virus-killing enzyme Cas13 – and a strand of guide RNA, which commands Cas13 to destroy specific nucleotide sequences in the coronavirus’s genome. By scrambling the virus’s genetic code, PAC-MAN could neutralize the coronavirus and stop it from replicating inside cells.
It’s all in the delivery
Qi said that the key challenge to translating PAC-MAN from a molecular tool into an anti-COVID-19 therapy is finding an effective way to deliver it into lung cells. When SARS-CoV-2, the coronavirus that causes COVID-19, invades the lungs, the air sacs in an infected person can become inflamed and fill with fluid, hijacking a patient’s ability to breathe.
“But my lab doesn’t work on delivery methods,” he said. So on March 14, they published a preprint of their paper, and even tweeted, in the hopes of catching the eye of a potential collaborator with expertise in cellular delivery techniques.
Soon after, they learned of Connolly’s work on synthetic molecules called lipitoids at the Molecular Foundry.
Lipitoids are a type of synthetic peptide mimic known as a “peptoid” first discovered 20 years ago by Connolly’s mentor Ron Zuckermann. In the decades since, Connolly and Zuckermann have worked to develop peptoid delivery molecules such as lipitoids. And in collaboration with Molecular Foundry users, they have demonstrated lipitoids’ effectiveness in the delivery of DNA and RNA to a wide variety of cell lines.
Today, researchers studying lipitoids for potential therapeutic applications have shown that these materials are nontoxic to the body and can deliver nucleotides by encapsulating them in tiny nanoparticles just one billionth of a meter wide – the size of a virus.
Now Qi hopes to add his CRISPR-based COVID-19 therapy to the Molecular Foundry’s growing body of lipitoid delivery systems.
In late April, the Stanford researchers tested a type of lipitoid – Lipitoid 1 – that self-assembles with DNA and RNA into PAC-MAN carriers in a sample of human epithelial lung cells.
According to Qi, the lipitoids performed very well. When packaged with coronavirus-targeting PAC-MAN, the system reduced the amount of synthetic SARS-CoV-2 in solution by more than 90%. “Berkeley Lab’s Molecular Foundry has provided us with a molecular treasure that transformed our research,” he said.
The team next plans to test the PAC-MAN/lipitoid system in an animal model against a live SARS-CoV-2 virus. They will be joined by collaborators at New York University and Karolinska Institute in Stockholm, Sweden.
If successful, they hope to continue working with Connolly and his team to further develop PAC-MAN/lipitoid therapies for SARS-CoV-2 and other coronaviruses, and to explore scaling up their experiments for preclinical tests.
“An effective lipitoid delivery, coupled with CRISPR targeting, could enable a very powerful strategy for fighting viral disease not only against COVID-19 but possibly against newly viral strains with pandemic potential,” said Connolly.
“Everyone has been working around the clock trying to come up with new solutions,” added Qi, whose preprint paper was recently peer-reviewed and published in the journal Cell. “It’s very rewarding to combine expertise and test new ideas across institutions in these difficult times.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Comparing SARS-CoV-2 Omicron BA.2 and BA.5 vaccine breakthrough infections
In a new study, investigators explored the SARS-CoV-2 Omicron BA.2 and BA.5 vaccine breakthrough infection likelihood.
- Multisystem Inflammatory Syndrome After Breakthrough SARS-CoV-2 Infection in 2 Immunized Adolescents, United States
Eight weeks after having laboratory-confirmed SARS-CoV-2 breakthrough infections, 2 otherwise healthy, fully immunized adolescent patients in the United States who were experiencing related signs ...
- Study estimates prevalence of SARS-CoV-2 omicron breakthrough infections in South Africa
In an article recently published in The Lancet journal, scientists have described the prevalence of vaccine breakthrough severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in ...
- Clinical and genomic signatures of SARS-CoV-2 Delta breakthrough infections in New York
We observed a modest adaptation of Delta genomes in breakthrough infections in New York, suggesting an improved genomic framework to support Delta's epidemic growth in times of waning vaccine ...
- Sharp Workspace Procat Photocatalyst Found Effective Against SARS- CoV-2
today announced a significant breakthrough achieved by Sharp’s Workspace Procat, a disinfect coating solution. Sharp’s new offering has been found effective against SARS-CoV-2 (Omicron variant ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- COVID-19 UPDATES: 713 new Idaho COVID-19 cases, 2 new deaths
Idaho officials reported 713 new COVID-19 cases and 2 new deaths over the weekend. State-level case and hospital data are now being updated on the state dashboard on Monday, Wednesday and Friday, ...
- Helixmith Announces Topline Results from Double-Blind Placebo Controlled Multicenter Study for TADIOS Involving 100 Subjects Infected with COVID-19
Serum levels of IL-1RA changed significantly, a biomarker that has a correlation with severity and mortality during COVID-19 infections LA JOLLA, Calif., Aug. 3, 2022 Helixmith announced topline ...
- A nasal vaccine could be key in curbing the spread of COVID-19
Story at a glance A nasal vaccine could be another weapon in the arsenal against COVID-19. Early research has shown promising results in terms of efficacy. Recent research published in Science ...
- Vaccination and BA.1 breakthrough infection induce neutralizing antibodies less efficient against BA.4 and BA.5 Omicron variants
A new study aimed to describe the appearance of the Omicron variants in Israel, from March to June 2022, as well as the neutralizing antibody response against the primary Omicron subvariants.
- SyneuRx Announces Final Results of Phase 2 Clinical Trial of COVID-19 Oral Antiviral Candidate Pentarlandir® (SNB01)
Eighty-nine participants suffering from breakthrough or unvaccinated cases of COVID-19 were randomized evenly into high-dose, low-dose, and placebo groups. The phase 2 study showed that Pentarlandir ...